BioSpace

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.

Por BioSpace

1 minuto de lectura
Compartir
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas